% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

  • insidetrack22 insidetrack22 Sep 3, 2013 11:43 AM Flag

    Herceptin's new formulation approved in Europe/Kadcyla to follow

    Based on CPMP actions, see below, I predict Kadcyla will be approved before year end in Europe. Watch for IMGN stock to fly. I am surprised, IMGN is not flying now.

    Investor Update
    Basel, 2 September 2013

    Roche’s new timesaving formulation of Herceptin approved in Europe for the treatment of HER2-positive breast cancer

    Subcutaneous formulation is administered in two to five minutes, rather than 30 to 90 minutes with the standard intravenous form
    Herceptin is used to treat more than 80,000 patients each year in Europe
    Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a new injectable (subcutaneous) formulation of Herceptin (trastuzumab) has been approved by the European Commission for the treatment of HER2-positive breast cancer, an aggressive sub-type of the disease. The approval is for both early and later stages of treatment.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.760.00(0.00%)Sep 28 4:00 PMEDT